Summary: ß 2 -Microglobulin and lysozyme were determined in paired serum and cerebrospinal fluid samples from 137 patients, using immunofluorometry and ELlSA, respectively. Of these patients, 54 were infected by human immunodeficiency virus type l (HIV1) (including 20 AIDS dementia patients), 73 were HIV1-seronegative with neurological diseases (meningitis (n = 10), multiple sclerosis (n = 29), other neurological diseases (n = 34)) and 10 were controls. Intrathecal synthesis of ß 2 -microglobulin occurred in each group. Conversely, lysozyme intrathecal synthesis was found only in meningitis (10/10) and in HIVI-infection (24/54). A pathological increase in ß 2 -microglobulin intrathecal synthesis (> 2mg/l) was observed in 45 patients (34 HIVl-infected patients and 11 HIV1-seronegative patients with neurological diseases). Serum concentration and intrathecal synthesis of ß 2 -microglobulin were correlated only in the 20 AIDS dementia patients. The cerebrospinal fluid ß 2 -microglobulin and lysozyme concentrations were correlated in the 54 HIVl-infected patients only. Blood CD4 + T-cell count was correlated negatively with ß 2 -microglobulin intrathecal synthesis but not with lysozyme intrathecal synthesis. These data suggest that in the absence of any central nervous system opportunistic process the increase of ß 2 -inicroglobulin intrathecal synthesis (> 2 mg/1) may be a reliable marker of central nervous system involvement in HIVl-infected patients. Intrathecal synthesis of lysozyme was related principally to HIV1-encephalitis and central nervous system opportunistic processes. ß 2 -Microglobulin is a low molecular mass ( 11 800) Encephalitis due to human immunodeficiency virus protein non-covalently bound to class I molecules of type 1 (HlVl)-infection (i. e. HIVI-encephalitis or the the major histocompatibility complex. ß 2 -Microglob-AIDS-dementia complex) is mainly encountered in ulin restricts antigen presentation (5) and elevated the late stages of infection (1). However, recent pa-serum ß 2 -microglobulin concentrations appear to be thobiological studies have suggested that early in-highly predictive of the onset or worsening of HIVIvolvement of the central nervous system may fre-disease (6-9). ß 2 -Microglobulin concentrations in quently occur (2-4). There are very few biological cerebrospinal fluid (CSF) can be elevated in both markers in clinical practice which effectively predict, asymptomatic HIVl-infected patients and AIDS padiagnose, and follow neurological involvement in tients (10, 11), suggesting that CSF ß 2 -microglobulin HIV1-infection.
involvement. Recently, a strong correlation between CSF ß 2 -microglobulin concentrations and AIDS-dementia complex severity was reported (12, 13) .
It was shown that ß 2 -microglobulin intrathecal synthesis is a physiological event in control subjects, and that its increase is correlated to neurological disorders in HIV1-infected patients. These results suggest that p 2 -microglobulin intrathecal synthesis may predict the spread of HIV1 to the central nervous system.
Patients
The 137 patients investigated were divided into three categories: 1) 54 HIVI-infected patients (48 men; 6 women; mean age 37 years) underwent diagnostic lumbar puncture at the Salpetriere hospital. According to the 1986 Centers for Disease Control classification (14, 15) iii) 34 other neurological disorders (23 men, 11 women; mean age 54 years): peripheral neuropathies (n = 12); dementias (n = 9); amyotrophic lateral sclerosis (n = 5); strokes (n = 5); myelopathies, (n = 3);
3) 10 control patients with no psychiatric or neurological disorders, and with serum and CSF quantities within normal limits (4 men, 6 women; mean age 49 years).
Methods ß 2 -Microglobulin assay
Paired serum and CSF samples were stored at -20 °C. Renal function, as assessed by serum creatinine concentrations, was normal in all patients. ß 2 -Microglobulin was determined using the Delfia System ß 2 -micro™ (Pharmacia, Uppsala, Sweden), a solid-phase time-resolved fluoroimmunoassay based on competition between europium-labelled ßrmicroglobulin and sample ß 2 -microglobulin for binding to a monoclonal antibody (16, 17) . Linearity was observed between 0.2 and 32 mg/1 of ß 2 -microglobulin. The detection limit of f the assay was 0.1 mg/l, the intra-assay precision less than 3.3%, and the inter-assay precision less than 7.5%.
Lysozyme assay
Lysozyme was determined in serum and CSF using a sandwichenzyme immuno assay (Eurodiag, Magny en Vexin, France), with an anti-lysozyme monoclonal antibody adsorbed to polystyrene beads, and revealed by an anti-lysozyme polyclonal antiserum labelled with horseradish peroxidase (18) . The assay was linear between 10 and 3000 g/l of lysozyme. The detection limit was 2 §/1. The intra-assay and inter-assay precisions were less than 5% and 9%, respectively.
Albumin, immunoglobulins (A, G, M) and C4 complement component assays These proteins were determined by electroimmunodiffusion in serum and CSF (19) using agarose alone or combined with hydroxyethylcellulose for IgA and IgM (20) , or carboxymethylcellulose for IgG (21) .
Assessment of intrathecal synthesis
Intrathecal synthesis of immunoglobulins and C4 complement component was taken as:
Maximal physiological filtration is the upper limit of normal (mean + two standard deviations) for each protein. Transudation was calculated from the normal mean CSF albumin concentration (210 mg/1 in our laboratory using an electroimmunodiffusion assay) and the transudation equivalence of each protein in comparison with albumin (22, 23) .
Lysozyme intrathecal synthesis can be calculated (in g/i) similarly: 
Meillet el al: Intrathecal ß 2 -microglobulin and lysozyme syntheses in AIDS where 60 §/1 is the upper limit of the lysozyme concentration in control CSF (mean: 38 ± 11 §/1) and 28 the transudation equivalence of lysozyme, based on its molecular mass.
This calculation method may not be suitable for ß 2 -microglobulin intrathecal synthesis. Control serum/CSF ratios were very low, as previously reported (24), suggesting a physiological synthesis. Despite very similar molecular masses (M r 11 800 for ß 2 -microglobulin and 14000 for lysozyme), the respective serum/CSF ratios in the controls were different (1.6 for ß 2 -microglobulin and 50 for lysozyme) (tab. 2). Extrapolation between the normal serum/CSF ratio for albumin (M T 63 000), which is 200, and the corresponding ratio for lysozyme, which is 50, gives an expected ratio of 40 for ß 2 -microglobulin, which differs from that observed. Thus, if the CSF albumin is ^210 mg/1, the ß 2 -microglobulin intrathecal synthesis (mg/1) can be taken as:
If plasma filtration is increased (CSF albumin > 210 mg/1), the previous ratio must be multiplied by the ratio: patient's CSF albumin/210, taking into account the ß 2 -microglobulin increase by plasma transudation. Since the molecular masses of ß 2 -microglobulin (M T 11 800) and lysozyme (M r 14000) are low compared with albumin (M T 63 000), the results of both formulae were compared with the protein/CSF albumin ratio for each protein, and with the index calculated for IgG (25) .
Peripheral blood CD4 + T-cell count
The absolute number of CD4 4-T-cells in peripheral blood was determined by flow cytometry, in the HIY1-infected patients only.
Statistical analysis
Group comparisons were made using the U-test of Mann & Whitney, the 2 test, and the Spearman's rank correlation.
Results ß 2 -Microglobulin and lysozyme concentrations in serum and CSF
The mean serum and CSF ß 2 -microglobulin and lysozyme concentrations in the patient groups are summarized in table 2. The mean serum ß 2 -microglobulin concentrations in the HIV1-infected patients was significantly higher than in HIVI-seronegative patients with neurological diseases or in the controls. Similar differences were observed in CSF, and there was also a significant difference between the AIDS dementia and other HIV1-infected patients. There was no correlation between serum and CSF ß 2 -microglobulin concentrations in the controls, multiple sclerosis, meningitis, or the 34 HIV1-infected patients without neurological disorders. In contrast, there was a highly significant correlation (p < 0.001) in the 20 AIDS dementia patients.
The mean serum lysozyme concentration in the HIV1 -infected patients did not differ significantly from that of the HIV1-seronegative patients with neurological diseases, or from that of the controls. CSF lysozyme concentrations were significantly higher in both subgroups of HIVI-infected patients than in the control group.
Using the CSF ß 2 -microglobulin/CSF lysozyme ratio proposed previously (26), we found a significant difference (p < 0.01) between both the meningitis patients (mean 17.8 ± 1.7) and the HIV1-infected patients (mean 58.5 + 8.4) and the controls (mean 28.8 ±3). . Among these 45 patients, the increase in ß 2 -microglobulin intrathecal synthesis was highly significant ( 2 = 23.7; < 0.001) in the 34 HIV1-infected patients compared with the 11 HIV1-seronegative patients. Using this assessment, the sensitivity of this marker in AIDS dementia was 63% and the specificity 85%, with a positive predictive value of 79% and a negative predictive value of 76%. Finally, the ratio K (positive predictive value/1-negative predictive value) was 3.3, clearly illustrating the relative risk of neurological disorders for a HIV1-infected patient with a pathological increase of ß 2 -microglobulin intrathecal synthesis.
Lysozyme intrathecal synthesis was much rarer, occurring in HIVI-infected patients and showing no difference between the 20 AIDS dementia and the 34 HIVI-infected patients without neurological disorders; it also occurred in 19 HIVI-seronegative patients with neurological diseases, of which 10 were infectious meningitis. In contrast to ß 2 -microglobulin intrathecal synthesis, lysozyme intrathecal synthesis was not detected in control CSF.
Correlations of intrathecal synthesis of ß 2 -microglobulin and lysozyme in the 54 HIV1-infected patients
In the 34 HIVI-infected patients with a pathological increase in ß 2 -microgobulin intrathecal synthesis (> 2 mg/1), there was a correlation between ß 2 -microglobulin and lysozyme intrathecal synthesis but no correlation with intrathecal synthesis of immunoglobulins (G, A, M) and complement C4. Conversely, in the 24 HIV1-infected patients with a ly$ozyme intrathecal synthesis, a significant correlation with IgG and IgM intrathecal synthesis (p < 0.01 and p < 0.001, respectively) was observed, but not with IgA or complement C4 intrathecal synthesis.
The mean blood CD4 + T-cell count was 183 ± 23.7 x 10 6 /1 in the 54 HIV1-infected patients without a significant difference between the means for the 20 AIDS dementia and the other 34 HIVI-infected patients. A negative correlation (p < 0.02) was found between the CD4 + T-cell count and serum ß 2 -microglobulin concentration, but this correlation was better (p < 0.001) with CSF ß 2 -microglobulin or ß 2 -microglobulin intrathecal synthesis ( fig. 1 ). Such correlations were not observed with serum lysozyme, CSF lysozyme or lysozyme intrathecal synthesis.
AIDS dementia and ß 2 -microglobulin intrathecal synthesis in HIV1-infected patients
As previously demonstrated, CSF ß 2 -microglobulin and ß 2 -microglobulin intrathecal synthesis were significantly higher in the 20 AIDS dementia patients than in the other 34 HIV1-infected patients. The highest mean ß 2 -microglobulin intrathecal synthesis (4.5 ± 0.5 mg/1) was observed in the 11 patients with HI VI-encephalitis. CD4+T cells [10 6 /l] ii) the significance and prognostic value of intrathecal ß 2 -microglobulin and lysozyme synthesis in HIV1-infected patients, compared with the HlVl-seronegative patients with neurological diseases.
As we previously demonstrated, ß 2 -microglobulin intrathecal synthesis is a physiological phenomenon, present in both controls and all the patients with neurological diseases. In contrast, lysozyme intrathecal synthesis appeared to be a pathological phenomenon related to an opportunistic process of the central nervous system, since it was not observed in the controls and rarely in the patients with neurological diseases. ß 2 -Microglobulin is found on the surface of lymphocytes in two molecular forms; the most abundant is associated with HLA class I antigen heavy chains, and the second is unbound to other membrane molecules (27) . It was recently demonstrated that this free ß 2 -microglobulin, in excess, promotes functional peptide association with purified soluble HLA class I molecules (28) . Of the estimated 100 mg ß 2 -microglobulin shed per day into the plasma, about half originates from lymphocytes (29) . From our data the daily intrathecal production of ß 2 -microglobulin is about 0.5 mg, given a daily CSF production of 500 ml.
During degradation of HLA heavy chains, the associated ß 2 -microglobulin may be shed into the cerebral extracellular fluid. ß 2 -Microglobulin is also expressed on the surface of glial cells (30) , macrophages and endothelial cells (31) . Whether or not the normal central nervous system expresses HLA class I antigens remains controversal, but the existence of physiological ß 2 -microglobulin intrathecal synthesis is, in our opinion, in favour of such expression. The normal brain is equipped to respond to immune stimulation, although low levels of lymphocyte traffic (estimated, from CSF cytology in normal subjects, as 500000 cells/day) probably occur. The precise origin of ß 2 -microglobulin intrathecal synthesis requires further investigation.
In pathological events, stimulation of immune cells (in particular lymphocytes and macrophages) and the activity of specific cytokines (such as -interferon) may contribute to increasing ß 2 -microglobulin concentrations via an enhancement of HLA class I expression on target cells. We suggest, like Me Arthur et al., that HIV1 replication within the brain and the accompanying inflammatory response increase the expression of class I molecules and account for the release of ß 2 -microglobulin. In demented patients, there may be greater class I expression than in nondemented subjects, leading to the presence of elevated CSF ß 2 -microglobulin (32). Inhibition of mitogenic responsiveness of peripheral blood mononuclear cells to phytohaemagglutinin, concanavalin A and poke-, weed mitogen was recently demonstrated using monoclonal antibodies to human ß 2 -microglobulin (33). Shedding of ß 2 -microglobulin from cells is enhanced during proliferation and differentiation. Moreover, it was recently shown that ß 2 -microglobulin possesses chemotactic activity for lymphoid cells and that it is identical to thymotaxin (34) , which may be involved in migration of bone marrow cells into the central nervous system. Increased ß 2 -microglobulin intrathecal synthesis might reflect a gradually increased lymphocyte mass and/or lymphocyte activity within the central nervous system. An alternative explanation is that ß 2 -microglobulin is released from necrotic tissue or proliferating glial cells. Such an increase was observed 10 years ago in patients with herpes encephalitis, mumps, and mononucleosis (26) . Despite the fact that ß 2 -microglobulin readily passes fenestrated blood vessels (eg. glomerular barrier or choroid plexus), such a mechanism cannot explain why the CSF ß 2 -microglobulin was higher than the serum ß 2 -microglobulin in 22 HIV1-infected patients. Such intrathecal synthesis was never observed with CSF lysozyme, and the major source of lysozyme is the lysosomes of polymorphonuclear leukocytes and macrophages. Assessment of lysozyme intrathecal synthesis (like complement C4 intrathecal synthesis) may offer a means of evaluating functional macrophage activity (35) . IgG and IgM intrathecal synthesis are indeed linked to lysozyme intrathecal synthesis, but not to ß 2 -microglobulin intrathecal synthesis. In other words, lysozyme intrathecal synthesis seems to be a marker of inflammation related to the HIV1 infection itself and the associated neurological opportunistic infections like toxoplasmosis, while any pathological (> 2 mg/1) increase of ß 2 -microglobulin intrathecal synthesis possibly reflects cell death and hyperactivation of lymphoid cells, glial cells and astrocytes. This is supported by the significant difference between patients with AIDS dementia and other E[IV1-infected patients without neurological disorders, and the correlation with the decrease of the CD4 + T-cell count. All these data suggest that in the absence of central nervous system opportunistic infections or neoplasms, a high replication within the brain and the accompanying inflammatory response of ßr-microglobulin intrathecal synthesis greater than 2 mg/1 have a good positive predictive value for the diagnosis of HIV1 dementia. Also, intrathecal synthesis of lysozyme may be a reliable predictor of HIV1 encephalitis and central nervous system opportunistic processes.
